Next 10 |
2024-04-24 07:15:00 ET Summary Sound Shore Fund, Inc. is registered as a diversified, open-end management investment company. The investment objective of the Fund is growth of capital. The Sound Shore Fund Investor Class and Institutional Class advanced 17.05% and 17.10%, respecti...
2024-04-22 10:55:53 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Tran...
2024-04-19 07:03:48 ET Summary Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing sales of next-generation drugs such as Ngenla, Bosul...
2024-04-19 06:55:31 ET More on Alvotech Alvotech (ALVO) Q4 2023 Earnings Call Transcript FDA approves Alvotech biosimilar of J&J top-selling drug Stelara Alvotech/Teva win FDA approval for Humira biosimilar Seeking Alpha’s Quant Rating on Alvotech ...
2024-04-19 05:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-17 09:26:31 ET More on CVS Health CVS Health: Seizing Opportunity Amid Recent Declines CVS Health: Good Management Is Keeping Their Promises CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential Dividend Roundup: P...
2024-04-16 18:22:06 ET More on Johnson & Johnson, Teva Pharmaceutical, etc. Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript Johnson & Johnson 2024 Q1 - Results - Earnings Call Presentation Johnson & Johnson: Doubling Down On This 2024 Dog Of ...
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnso...
2024-04-16 12:54:17 ET More on AbbVie AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% AbbVie working with FDA after reports of fake Botox versions ...
Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START study results further support real-world effectiveness, safety, adherence and patient satisfaction with the 4...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
The U.S. Supreme Court has reportedly chosen not to review Vanda Pharmaceuticals Inc’s (NASDAQ:VNDA) attempt to revive patents...
2024-04-19 05:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnso...